Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed outlook: strong product innovation and market strategy are offset by uncertainties in tariffs and CMS proposals. The Q&A session reveals management's cautious optimism, but with some unclear responses. Financial performance and guidance remain stable, yet the lack of clear answers on certain risks tempers enthusiasm. Given these factors, a neutral rating is appropriate as the stock may not significantly change over the next two weeks.
Key Financial Performance
Revenue $1.6 billion in Q2 2025, with 6.7% underlying growth and 7.8% reported growth. The growth included a 110 basis point tailwind from foreign exchange and a headwind from one fewer trading day compared to the prior year. U.S. revenue grew 8.7%, other established markets grew 7.4%, and emerging markets declined 0.2% due to easing impacts of volume-based procurement in China.
Profitability 100 basis points of trading margin expansion in the first half of 2025, slightly ahead of expectations due to accelerated efficiency savings. Trading profit grew 11.2% to $523 million, with a margin of 17.7%, up 100 basis points year-over-year. Margin expansion was driven by revenue leverage, productivity improvements, and operational savings.
Free Cash Flow $244 million in the first half of 2025, a 500% increase year-over-year. This improvement was driven by lower restructuring costs, better inventory management, and operational efficiencies.
Trading Cash Flow $487 million in the first half of 2025, with a trading cash conversion of 93%, up from 60% in the first half of 2024. The improvement was due to lower working capital outflows and inventory day reductions.
Gross Profit $2.1 billion in the first half of 2025, with a gross margin of 70.5%, a 40 basis point increase year-over-year. This was driven by positive variances in price and volume.
Orthopaedics Revenue $3 billion in the first half of 2025, with 4.1% growth year-over-year. Margin expansion of 230 basis points was achieved through inventory reduction, portfolio simplification, and focus on higher volume accounts.
Sports Medicine and ENT Revenue 4.1% growth in the first half of 2025. Excluding China, growth would have been 9%. Margin declined 130 basis points due to volume-based procurement in China.
Advanced Wound Management Revenue 7.1% growth in the first half of 2025. Margin increased 160 basis points due to mix, efficiency gains, and timing of revenues.
Inventory Days Reduced by 46 days to 506 inventory days in the first half of 2025, resulting in a $69 million reduction in inventory value at constant currency. This was achieved through better forecasting and production alignment.
Earnings Per Share (EPS) Adjusted EPS grew 14% to $0.429 in the first half of 2025, driven by revenue leverage, operational savings, and lower restructuring costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Sports Medicine: Maintained strong momentum in Joint Repair and AET outside of China. Joint Repair growth was 8.4%, with double-digit growth in knee, shoulder, and hip repair. Key contributors include REGENETEN and Q-FIX KNOTLESS suture anchors.
Orthopaedics: Delivered 5.5% underlying growth. U.S. Hips and Knees showed 2% underlying growth, with strong performance from the CATALYSTEM Hip System. Robotics placements grew, particularly in the U.S., supported by the launch of CORIOGRAPH for shoulder replacements.
Advanced Wound Management: Growth increased to 10.2%, led by Bioactives and Advanced Wound Devices. Bioactives saw a rebound in SANTYL and double-digit growth in skin substitutes. Advanced Wound Devices grew 12.7%, driven by PICO and Leaf systems.
Geographical Growth: U.S. grew 8.7%, other established markets grew 7.4%, and emerging markets (excluding China) grew 12.2%. China impacts are easing, with destocking expected to reduce further in the second half.
U.S. Department of Defense Contract: Awarded a $75 million contract for RENASYS TOUCH, a traditional negative pressure wound therapy system, with an initial term of 5 years, extendable to 10 years.
Profitability: Achieved 100 basis points of trading margin expansion in the first half, with full-year margin guidance of 19%-20%. Operational savings and manufacturing network optimization contributed to this improvement.
Cash Flow: Trading cash flow increased by 70%, with $250 million in free cash flow in the first half. A $500 million share buyback is planned for the second half, funded by cash flow and existing balances.
Inventory Management: Reduced days of inventory by 46 days, contributing to a $69 million reduction in inventory value. Improved forecasting and production alignment are ongoing.
12-Point Plan: Continued progress in operational efficiencies, including Orthopaedics transformation and cost savings. Delivered $50 million in savings in the first half, with a total of $275-$285 million expected by year-end.
Innovation: 75% of revenue growth in H1 came from products launched in the last 5 years. Key innovations include the TRIGEN MAX Tibia Nailing System, CORIOGRAPH for shoulder replacements, and expanded use of REGENETEN.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs: Uncertainty about where tariffs will settle, with an expected net headwind of $15 million to $20 million in 2025, mainly impacting the second half of the year.
China Market Challenges: Volume-based procurement (VBP) in China has been a significant headwind, particularly in Orthopaedics and Sports Medicine. Although the impact is easing, it continues to affect sales and profitability.
Medicare Reimbursement Changes: Proposed updates to Medicare reimbursement for skin substitutes in the outpatient and physician office setting could negatively impact Advanced Wound Management sales and profitability in 2026.
Supply Chain and Inventory Management: While inventory levels have improved, further alignment of production plans with commercial needs is required. Forecasting and production planning at the SKU level remain areas for improvement.
R&D Spending: A shortfall in R&D spending in the first half of 2025 is expected to be caught up in the second half, which could strain resources and impact innovation timelines.
Competitive Pressures: Slower growth in certain product lines, such as U.S. Knees, due to competitive pressures and a focus on streamlining the portfolio.
Economic Uncertainties: Foreign exchange fluctuations have impacted revenue, with a 30 basis point headwind in the first half of 2025, although this turned into a tailwind in the second quarter.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects a step-up in revenue growth in the second half of 2025, driven by easing headwinds in China and continued momentum in Sports Medicine and Wound Management. Full-year revenue growth is projected to be in line with the current guidance.
Profitability and Margins: The company remains on track to achieve its full-year trading margin guidance of 19% to 20%, with a step-up in margin expected in the second half of 2025. This will be supported by cost savings, reduced headwinds from value-based procurement in China, and operational efficiencies.
China Market Recovery: The company expects the headwinds from distributor destocking in Orthopaedics and value-based procurement in China to ease in the second half of 2025, contributing to improved performance in the region.
Product Launches and Innovation: The company plans to accelerate the deployment of the CATALYSTEM Hip System in Q3 2025 and expand its availability to other markets, starting with Japan. Additional product launches, including new features for CORI Robotics and the TRIGEN MAX Tibia Nailing System, are expected to drive growth.
Advanced Wound Management: The company anticipates mid-single-digit growth for Bioactives in 2025, despite tougher competition in the second half. However, potential Medicare reimbursement changes in 2026 could pose a headwind to sales and profitability.
Free Cash Flow and Shareholder Returns: The company expects to generate well over $600 million in free cash flow for 2025 and has announced a $500 million share buyback in the second half of the year, funded by cash flow and existing balances.
Tariff Impact: The company anticipates a net headwind of $15 million to $20 million from tariffs in 2025, primarily impacting the second half of the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Interim Dividend: The interim dividend of $0.15 per share is up 4.2% on Half 1 2024, in line with the policy of paying 40% of prior year full year dividend as the interim dividend.
Share Buyback Program: A $500 million share buyback is planned for the second half of 2025. This will be fully financed from free cash flow and existing cash balances, ensuring it does not compromise growth ambitions or leverage ratios.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:With Q2 being stronger than expected, does this imply upside to the 5% revenue target for the full year, or are you expecting a slowdown elsewhere in the business?
A:Management feels good about the guidance for the full year, considering both positives and negatives. They expect a step-up in revenue and profit in the back half of the year but are maintaining the 5% target due to an uncertain environment and various factors like tariffs and China VBP.
Q:Could you walk us through the bridge in H2 margin and whether the upper end of the 19%-20% margin range is achievable?
A:Management expects to maintain the 19%-20% margin guidance. They highlighted factors like cost inflation, VBP impact, revenue leverage, and operating savings contributing to the margin. They expect to end the year at the center of the range.
Q:Can you provide more detail on the work being done in U.S. Knees and the factors driving weakness in this segment?
A:Management is focusing on refocusing the commercial organization on higher-volume accounts and rationalizing the portfolio to two knee platforms (LEGION and JOURNEY). They also noted a slowdown in procedures among active surgeons and surgeon transitions as contributing factors.
Q:What are the drivers of operating savings in H2, and how well advanced are these programs?
A:The savings come from manufacturing, procurement, warehousing, distribution, business support, and sales and marketing. There are 51 programs, most of which are already in progress or complete. Management is confident in achieving the savings.
Q:Why was there a slowdown in procedures among active surgeons in U.S. Knees, and has this continued into Q3?
A:Management noted a slowdown in procedures among active surgeons, possibly due to vacation schedules and surgeon transitions. They are uncertain about the exact reasons but have seen some improvement in churn and operational progress.
Q:Has the lower-cost inventory from site closures started to flow through, and what is the impact on margins?
A:The benefits of network optimization efforts will fully manifest in H2, but some impact has already been seen. Management expects this to be a key driver of margin improvement in the second half of the year.
Q:Have you explored the Nairobi Treaty to avoid tariffs on Hips and Knees?
A:Management is exploring all options, including the Nairobi Treaty, but currently expects a $15-$20 million impact from tariffs. They noted that most of their Orthopaedics production is U.S.-based, which mitigates some impact.
Q:How are you thinking about ending the year in terms of net debt to EBITDA, given the strong cash flow in H1?
A:Management expects to end the year below their 2x net debt-to-EBITDA target, even with the $500 million buyback, leaving capacity for growth ambitions.
Q:What is the outlook for inventory levels and cash generation in the medium term?
A:Management expects continued improvement in inventory levels, particularly in Orthopaedics, which will free up cash. They are already seeing progress in inventory health and slow-turning inventory levels.
Q:What are the market share gains expected from CATALYSTEM in Hips, especially in the ASC channel?
A:Management is pleased with the uptake of CATALYSTEM, which has received positive surgeon feedback. They expect it to drive market share gains across various settings, including ASCs, hospitals, and academic centers.
Q:What is the demand and placement trend for CORI Robotics, and how is it split between hospital and ASC channels?
A:Management is focusing on both placements and utilization of CORI Robotics. They noted strong uptake in ASCs due to its size, footprint, and lower capital cost, which makes it well-suited for this channel.
Q:What are the drivers of double-digit growth in Joint Repair, excluding China, and how sustainable is this growth?
A:Key drivers are Q-FIX and REGENETEN, with increasing adoption in rotator cuff and Achilles indications. Management expects REGENETEN to be a platform technology, driving sustainable growth.
Q:What is the exposure to the new CMS proposal on skin substitutes, and what mitigating actions are being taken?
A:Management expects a net headwind from the new CMS proposal, with pricing changes impacting revenue and profit. They are committed to developing products with strong clinical evidence and maintaining a strong presence in hospitals.
Q:What is the pipeline for bolt-on acquisitions, and how does the buyback impact this?
A:Management has an active pipeline for bolt-on acquisitions and does not feel constrained by the announced buyback. They view M&A as a key part of value creation in MedTech.
Q:What is the strategic position of Orthopaedics within the company, and how does it align with the 12-Point Plan?
A:Management is focused on improving Orthopaedics' performance through product availability, commercial execution, and margin expansion. They believe this is the best way to drive shareholder value and are making progress.
Q:What is the trajectory for margins beyond 2025, and how does the savings plan impact this?
A:Management expects continued margin expansion beyond 2025, with Orthopaedics margins improving further. They plan to provide more details at the Capital Market Day and after full-year 2025 results.
Q:What is the sustainability of growth and the future pipeline of products?
A:Management is committed to innovation, with 75% of H1 growth from products launched in the past 5 years. They expect to build on this and will detail growth drivers at the Capital Market Day.
Q:Are you still targeting market growth rates in U.S. Recon by year-end, and how do you plan to achieve this?
A:Management remains committed to reaching market growth rates in U.S. Recon, aiming for progress in both Knees and Hips. They expect to achieve this at the U.S. Recon level, even if the shape of growth varies.
Q:What is the nature of discussions with Sapient, and what influence have they had?
A:Management has had open and constructive discussions with Sapient, similar to their engagement with other shareholders. They plan to maintain this approach.
Q:Is the Nairobi protocol being used to mitigate tariffs?
A:No, the Nairobi protocol is not currently being used to mitigate tariffs.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to the reasons behind the slowdown in procedures among active surgeons in U.S. Knees, citing uncertainty and speculating on factors like vacation schedules and surgeon transitions. They also did not provide specific details on the impact of the new CMS proposal on skin substitutes, including pricing and volume changes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advanced Wound
Bank
Bioactives
Deepak
Hips Knees
Joint Repair
Orthopaedics
RD
Recon Robotics
Research Division
Sports Medicine
VBP China
acceleration
accretion
capital allocation
cash conversion
cash flow
cash return
destocking
dividend
efficiency
flow cash
leverage
margin basis
margin expansion
period
process
profitability cash
reduction
restructuring
share buyback
start term
tariff
SNN Transcript
Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call highlighted strong financial performance with a 21% EPS increase and a $500 million share buyback. Trading margins expanded, and ROIC improved. Product updates like the CORI Shoulder platform and REGENETEN's market potential were promising. Despite some uncertainties in China and the skin substitutes market, the company maintains a positive outlook for 2026 with growth in key areas. The Q&A reflected confidence in strategic initiatives and competitive positioning, supporting a positive sentiment.
Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call summary presents a mixed outlook: strong product innovation and market strategy are offset by uncertainties in tariffs and CMS proposals. The Q&A session reveals management's cautious optimism, but with some unclear responses. Financial performance and guidance remain stable, yet the lack of clear answers on certain risks tempers enthusiasm. Given these factors, a neutral rating is appropriate as the stock may not significantly change over the next two weeks.
Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript
Unknown5-2
The earnings call presents a mixed picture: moderate revenue growth, strong performance in specific segments, and effective tariff mitigation strategies, but also challenges like headwinds in China and lack of share buybacks. The Q&A reveals optimism about future growth and margin improvements, but some concerns remain unaddressed. The absence of a share buyback program and the challenges in emerging markets balance the positives, leading to a neutral stock price prediction over the next two weeks.
Smith & Nephew plc (SNN) Q4 2024 Earnings Call Transcript
Unknown2-25
The earnings call presents a mixed picture. Financial performance shows growth in revenue and trading profit, but gross margins have declined slightly. The unchanged dividend and improved free cash flow are positive, while headcount reductions and cost savings indicate efficiency efforts. However, management's unclear responses in the Q&A, particularly regarding inventory reduction and competitive dynamics in China, suggest some uncertainty. The overall sentiment is neutral, with no strong catalysts for significant stock movement in the short term.
SNN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
